Quince Therapeutics Inc logo

Quince Therapeutics Inc

2
NAS:QNCX (USA)  
$ 1.75 +0.04 (+2.34%) 08:08 PM EST
At Loss
P/B:
1.68
Market Cap:
$ 77.00M
Enterprise V:
$ 42.85M
Volume:
195.31K
Avg Vol (2M):
811.22K
Trade In:
Volume:
195.31K
At Loss
Avg Vol (2M):
811.22K

Business Description

Description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Name Current Vs Industry Vs History
Cash-To-Debt 3.1
Equity-to-Asset 0.36
Debt-to-Equity 0.34
Debt-to-EBITDA -0.46
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.55
9-Day RSI 35.08
14-Day RSI 43.93
6-1 Month Momentum % 178.01
12-1 Month Momentum % 73.45

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.53
Quick Ratio 9.53
Cash Ratio 8.82

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -13.3
Shareholder Yield % -18.87
Name Current Vs Industry Vs History
ROE % -79.67
ROA % -39.52
ROIC % -50.55
ROC (Joel Greenblatt) % -5641.85
ROCE % -27.03

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.68
EV-to-EBIT -1.25
EV-to-Forward-EBIT -1.06
EV-to-EBITDA -1.26
EV-to-Forward-EBITDA -0.01
EV-to-FCF -1.47
Earnings Yield (Greenblatt) % -80
FCF Yield % -39.68

Financials (Next Earnings Date:2025-02-13 Est.)

QNCX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:QNCX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Quince Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.24
Beta 1.62
Volatility % 118.71
14-Day RSI 43.93
14-Day ATR ($) 0.20024
20-Day SMA ($) 1.9505
12-1 Month Momentum % 73.45
52-Week Range ($) 0.5116 - 2.45
Shares Outstanding (Mil) 44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Quince Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Quince Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Quince Therapeutics Inc Frequently Asked Questions

What is Quince Therapeutics Inc(QNCX)'s stock price today?
The current price of QNCX is $1.75. The 52 week high of QNCX is $2.45 and 52 week low is $0.51.
When is next earnings date of Quince Therapeutics Inc(QNCX)?
The next earnings date of Quince Therapeutics Inc(QNCX) is 2025-02-13 Est..
Does Quince Therapeutics Inc(QNCX) pay dividends? If so, how much?
Quince Therapeutics Inc(QNCX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1